PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Global chronic lymphocytic leukemia market set to reach $9.2bn by 2027, says GlobalData

The chronic lymphocytic leukemia (CLL) market is expected to grow from $7.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 1.8%, according to GlobalData, a leading data and analytics company.
The company’s latest report: Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027, states that the main driver of the growth of the global CLL market in the next ten years will be the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens.
Francesca Blum, MSci, UK Oncology Director at GlobalData, says: “The modest growth of the CLL market will be driven by increasing incidence, primarily by aging populations, as well as label expansions into the first-line setting for AbbVie/Roche’s Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnson’s Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens.
“Non-toxic therapies that have a fixed duration of treatment are expected to play an increasingly large role in the CLL market, which can be achieved using combinations of targeted drugs.”
Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period.
Blum continues: “A major barrier for market growth in CLL will be the increased use of rituximab biosimilars and generic ibrutinib, which will erode sales of current standards of care Rituxan and Imbruvica.
“In addition, novel targeted agents such as AstraZeneca’s Calquence (acalabrutinib), and TG Therapeutics’ umbralisib will enter the market during the forecast period, but overall, a lack of innovative drugs in the late-stage pipeline with novel mechanisms of action, means that next-generation agents are not expected to generate significant sales.”
GlobalData’s report also found that novel research and development strategies are being investigated in early-stage clinical trials for the treatment of CLL.
Blum concludes: “Several immunotherapies are in early-stage development, primarily checkpoint inhibitors and chimeric antigen receptor T cell therapies, so in future, CLL may also be treatable with immuno-oncology regimens, as is already the case for other hematological malignancies such as acute lymphocytic leukemia and diffuse large B-cell lymphoma.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026